We are expanding our world-class executive team to include Dave Rosin as Vice President, Business Development.
Rosin is joining ElleVet from the strategic consulting world. He was most recently an associate partner at the global management consulting firm McKinsey & Company and a growth strategy manager at Monitor Deloitte Monitor.
A native of Toronto, Canada, Rosin earned his bachelor of commerce degree at McGill University in Montreal and attended ESADE School of Business in Barcelona, Spain. He is fluent in English, Spanish, and Hebrew and has traveled to over 40 countries.
“Dave’s consulting background strengthens our analytical bandwidth and allows ElleVet Sciences to continue to pursue multiple growth opportunities within the cannabinoid industry,” says Christian Kjaer, CEO of ElleVet Sciences. “He will play a crucial role in helping the ElleVet team reach a greater number of pets in need, which is our ultimate goal as a company.”
“I couldn’t be more excited to join the ElleVet Sciences team,” says Rosin. “I am eager to learn more about CBD in the animal health field and leverage my background of analytics and strategic insight to fuel ElleVet’s next wave of growth.”
We conducted the first clinical trial using its product on dogs with osteoarthritis in conjunction with Dr. Joe Wakshlag, ElleVet’s chief medical officer and professor at Cornell University’s College of Veterinary Medicine. Our product remains the only pet CBD + CBDA product that is proven to work in a clinical trial. We currently have more than 30 ongoing clinical studies and R&D projects and expect to finalize several clinical studies in 2021.